Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients.
Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients.
复制标题
DOI：
10.1371/journal.pone.0093886
复制
发表时间：
2014
期刊：
影响因子：
3.7
通讯作者：
Li JJ
中科院分区：
文献类型：
--
作者：
Gao D;Li C;Xie X;Zhao P;Wei X;Sun W;Liu HC;Alexandrou AT;Jones J;Zhao R;Li JJ
胃癌和结直肠癌（GC 和 CRC）预后不良，并且对化疗和/或放疗具有抵抗力。在本研究中，评估了一组 54 名 GC 和 CRC 患者在术后接受或不接受放化疗的情况下接受树突状细胞 (DC) 免疫治疗联合细胞因子诱导杀伤 (CIK) 细胞治疗的树突状细胞 (DC) 疫苗接种对疾病进展和临床益处的预防效果。使用IL-2/GM-CSF从患者分离的单核细胞制备DC，并负载肿瘤抗原； CIK细胞通过将外周血淋巴细胞与IL-2、IFN-γ和CD3抗体一起孵育来制备。 DC/CIK治疗于低剂量化疗后3天开始，2周内重复3~5次为1个周期，总共188.3±79.8×106个DC和58.8±22.3×108个CIK细胞。测量治疗前后患者血清中的细胞因子水平，并随访 98 个月以确定无病生存期 (DFS) 和总生存期 (OS)。结果表明，在 DC/CIK 治疗患者的 GC 和 CRC 队列中，所有测试的细胞因子均升高，其中 IFN-γ 和 IL-12 水平显着升高。通过 Cox 回归分析，DC/CIK 治疗降低了术后疾病进展的风险 (p<0.01)，同时 OS 增加 (<0.01)。这些结果表明，除了化疗和/或放疗之外，DC/CIK 免疫疗法是控制术后 GC 和 CRC 患者肿瘤生长的潜在有效方法。
Gastric and colorectal cancers (GC and CRC) have poor prognosis and are resistant to chemo- and/or radiotherapy. In the present study, the prophylactic effects of dendritic cell (DC) vaccination are evaluated on disease progression and clinical benefits in a group of 54 GC and CRC patients treated with DC immunotherapy combined with cytokine-induced killer (CIK) cells after surgery with or without chemo-radiotherapy. DCs were prepared from the mononuclear cells isolated from patients using IL-2/GM-CSF and loaded with tumor antigens; CIK cells were prepared by incubating peripheral blood lymphocytes with IL-2, IFN-γ, and CD3 antibodies. The DC/CIK therapy started 3 days after low-dose chemotherapy and was repeated 3–5 times in 2 weeks as one cycle with a total of 188.3±79.8×106 DCs and 58.8±22.3×108 CIK cells. Cytokine levels in patients' sera before and after treatments were measured and the follow-up was conducted for 98 months to determine disease-free survival (DFS) and overall survival (OS). The results demonstrate that all cytokines tested were elevated with significantly higher levels of IFN-γ and IL-12 in both GC and CRC cohorts of DC/CIK treated patients. By Cox regression analysis, DC/CIK therapy reduced the risk of post-operative disease progression (p<0.01) with an increased OS (<0.01). These results demonstrate that in addition to chemo- and/or radiotherapy, DC/CIK immunotherapy is a potential effective approach in the control of tumor growth for post-operative GC and CRC patients.
登录
查看更多内容
影响因子：
6.2
作者：
Higano, Celestia S.;Schellhammer, Paul F.;Frohlich, Mark W.
通讯作者：
Frohlich, Mark W.
影响因子：
158.5
作者：
Kantoff, Philip W.;Higano, Celestia S.;Young, J.
通讯作者：
Young, J.
DOI：
10.1093/jnci/djr514
发表时间：
2012-02-22
期刊：
Journal of the National Cancer Institute
影响因子：
--
作者：
Huber ML;Haynes L;Parker C;Iversen P
通讯作者：
Iversen P
影响因子：
6.7
作者：
González-Carmona, MA;Märten, A;Caselmann, WH
通讯作者：
Caselmann, WH
影响因子：
120.1
作者：
Higano, Celestia S.;Small, Eric J.;Kantoff, Philip W.
通讯作者：
Kantoff, Philip W.